Display options
Cite
Cai J, Zeng C, Hua W, et al. An integrative analysis of genome-wide 5-hydroxymethylcytosines in circulating cell-free DNA detects noninvasive diagnostic markers for gliomas. Neurooncol Adv. 2021;3(1):vdab049doi: 10.1093/noajnl/vdab049.
Cai, J., Zeng, C., Hua, W., Qi, Z., Song, Y., Lu, X., Li, D., Zhang, Z., Cui, X., Zhang, X., Yang, Z., Zhang, J., Quan, K., Zhu, W., Cai, J., He, C., Cheng, S. Y., Zhang, W., & Mao, Y. (2021). An integrative analysis of genome-wide 5-hydroxymethylcytosines in circulating cell-free DNA detects noninvasive diagnostic markers for gliomas. Neuro-oncology advances, 3(1), vdab049. https://doi.org/10.1093/noajnl/vdab049
Cai, Jiajun, et al. "An integrative analysis of genome-wide 5-hydroxymethylcytosines in circulating cell-free DNA detects noninvasive diagnostic markers for gliomas." Neuro-oncology advances vol. 3,1 (2021): vdab049. doi: https://doi.org/10.1093/noajnl/vdab049
Cai J, Zeng C, Hua W, Qi Z, Song Y, Lu X, Li D, Zhang Z, Cui X, Zhang X, Yang Z, Zhang J, Quan K, Zhu W, Cai J, He C, Cheng SY, Zhang W, Mao Y. An integrative analysis of genome-wide 5-hydroxymethylcytosines in circulating cell-free DNA detects noninvasive diagnostic markers for gliomas. Neurooncol Adv. 2021 Apr 16;3(1):vdab049. doi: 10.1093/noajnl/vdab049. eCollection 2021. PMID: 34151267; PMCID: PMC8209591.
Copy Download .nbib Format: NLM
Share it on

Neurooncol Adv. 2021 Apr 16;3(1):vdab049. doi: 10.1093/noajnl/vdab049. eCollection 2021.

An integrative analysis of genome-wide 5-hydroxymethylcytosines in circulating cell-free DNA detects noninvasive diagnostic markers for gliomas.

Neuro-oncology advances

Jiajun Cai, Chang Zeng, Wei Hua, Zengxin Qi, Yanqun Song, Xingyu Lu, Dongdong Li, Zhou Zhang, Xiaolong Cui, Xin Zhang, Zixiao Yang, Jinsen Zhang, Kai Quan, Wei Zhu, Jiabin Cai, Chuan He, Shi-Yuan Cheng, Wei Zhang, Ying Mao

Affiliations

  1. Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
  2. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  3. Shanghai Epican Genetech Co., Ltd., Shanghai, China.
  4. Department of Chemistry, The University of Chicago, Chicago, Illinois, USA.
  5. Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
  6. The Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  7. State Key Laboratory of Medical Neurobiology, School of Basic Medical Sciences, and The Collaborative Innovation Centre for Brain Science, Fudan University, Shanghai, China.

PMID: 34151267 PMCID: PMC8209591 DOI: 10.1093/noajnl/vdab049

Abstract

BACKGROUND: Gliomas, especially the high-grade glioblastomas (GBM), are highly aggressive tumors in the central nervous system (CNS) with dismal clinical outcomes. Effective biomarkers, which are not currently available, may improve clinical outcomes through early detection. We sought to develop a noninvasive diagnostic approach for gliomas based on 5-hydroxymethylcytosines (5hmC) in circulating cell-free DNA (cfDNA).

METHODS: We obtained genome-wide 5hmC profiles using the 5hmC-Seal technique in cfDNA samples from 111 prospectively enrolled patients with gliomas and 111 age-, gender-matched healthy individuals, which were split into a training set and a validation set. Integrated models comprised 5hmC levels summarized for gene bodies, long noncoding RNAs (lncRNAs),

RESULTS: The integrated 5hmC-based models differentiated healthy individuals from gliomas (area under the curve [AUC] = 84%; 95% confidence interval [CI], 74-93%), GBM patients (AUC = 84%; 95% CI, 74-94%), WHO II-III glioma patients (AUC = 86%; 95% CI, 76-96%), regardless of

CONCLUSIONS: The 5hmC-Seal in cfDNA offers the promise as a noninvasive approach for effective detection of gliomas in a screening program.

© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

Keywords: 5-hydroxymethylcytosine; biomarker; cell-free DNA; diagnosis; glioma

References

  1. Curr Cancer Drug Targets. 2010 Dec;10(8):840-8 - PubMed
  2. Neuropathol Appl Neurobiol. 2018 Feb;44(2):139-150 - PubMed
  3. Nat Med. 2020 Jul;26(7):1044-1047 - PubMed
  4. Cancer Biol Med. 2017 Feb;14(1):90-99 - PubMed
  5. J Biol Chem. 2015 Feb 6;290(6):3814-24 - PubMed
  6. Nature. 2015 Feb 19;518(7539):317-30 - PubMed
  7. Nat Commun. 2016 Nov 25;7:13177 - PubMed
  8. Acta Neuropathol. 2016 Jun;131(6):803-20 - PubMed
  9. Cell Res. 2017 Oct;27(10):1243-1257 - PubMed
  10. Oncotarget. 2018 May 25;9(40):25922-25934 - PubMed
  11. Nat Rev Genet. 2011 Nov 15;13(1):7-13 - PubMed
  12. Cancers (Basel). 2010 May 26;2(2):1013-26 - PubMed
  13. Nat Commun. 2015 Nov 10;6:8839 - PubMed
  14. Gut. 2019 Dec;68(12):2195-2205 - PubMed
  15. Neuro Oncol. 2015 Mar;17(3):343-60 - PubMed
  16. Nat Rev Clin Oncol. 2017 Jul;14(7):434-452 - PubMed
  17. Int J Mol Sci. 2018 May 30;19(6): - PubMed
  18. PLoS One. 2014 Feb 21;9(2):e89376 - PubMed
  19. Brain Pathol. 2018 Sep;28(5):695-709 - PubMed
  20. J Biol Chem. 2014 Jun 20;289(25):17689-98 - PubMed
  21. Nat Rev Mol Cell Biol. 2019 Oct;20(10):590-607 - PubMed
  22. Acta Neuropathol. 2015 Jun;129(6):849-65 - PubMed
  23. Curr Neurol Neurosci Rep. 2013 May;13(5):345 - PubMed
  24. AJNR Am J Neuroradiol. 2018 Jul;39(7):1201-1207 - PubMed
  25. JAMA. 2013 Nov 6;310(17):1842-50 - PubMed
  26. Front Genet. 2016 Feb 09;7:11 - PubMed
  27. Cell. 2016 Jan 28;164(3):550-63 - PubMed
  28. Oncogene. 2013 Feb 28;32(9):1099-109 - PubMed
  29. Mol Cell. 2016 Aug 18;63(4):711-719 - PubMed
  30. Proc IEEE Int Symp Biomed Imaging. 2018 Apr;2018:1529-1533 - PubMed
  31. Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2421-6 - PubMed
  32. Nature. 2019 Jan;565(7741):654-658 - PubMed
  33. Curr Biol. 2002 Jun 25;12(12):R429-31 - PubMed
  34. Biomed Res Int. 2017;2017:8013575 - PubMed
  35. Cell Death Dis. 2016 Dec 1;7(12):e2494 - PubMed
  36. Nat Commun. 2020 Dec 2;11(1):6161 - PubMed
  37. J Digit Imaging. 2017 Aug;30(4):469-476 - PubMed
  38. Nucleic Acids Res. 2019 Jan 8;47(D1):D419-D426 - PubMed
  39. Nucleic Acids Res. 2000 Jan 1;28(1):27-30 - PubMed
  40. EPMA J. 2013 Feb 25;4(1):7 - PubMed
  41. Clin Cancer Res. 2018 Jun 15;24(12):2812-2819 - PubMed
  42. Biometrics. 1989 Mar;45(1):255-68 - PubMed

Publication Types

Grant support